Public Policy Resources

Our latest Survivor Views survey sees increases in biomarker testing since the question was last asked three years ago along with reduced cost and coverage barriers in that time. Cancer patients and survivors describe the benefits and overwhelmingly agree biomarker testing gave their providers information that improved their treatment. 

ACS CAN and partner organizations provided comments on the Medicare Drug Price Negotiation Program: Considerations for Selected Oncology Drugs.

ACS CAN strongly advocated for inclusion in the Inflation Reduction Act of both an annual cap on total Part D out-of-pocket costs and a mechanism that would allow an enrollee the option to pay the required cost-sharing in capped monthly installments because we know from research that hig

ACS and ACS CAN provided comments to the Centers for Medicare and Medicaid Services on the list of Part D drugs selected for the price negotiation program authorized under the Inflation Reduction Act (IRA).

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2024 Medicare Physician Fee Schedule.

Access to care for those who are uninsured not only ensures that serious diseases like cancer can be detected and treated earlier but also often means better patient outcomes and less costs to the individual and the larger health care system.

The American Cancer Society Cancer Action Network (ACS CAN) provided the following statement for the record at the House Energy & Commerce Health Subcommittee Hearing on Legislative Solutions to Bolster Preparedness and Response for all Hazards and Public Health Security Threats on June 13, 2023.

The American Cancer Society Cancer Action Network (ACS CAN) provided the following statement for the record at the House Energy & Commerce Oversight Hearing on Examining the Root Causes of Drug Shortages: Challenges in Pharmaceutical Drug Supply Chains on May 11, 2023.

Our latest survey finds that cancer patients and survivors would be less likely to stay current with preventive care, including recommended cancer screenings, if the provision requiring these services be covered at no cost were repealed. This survey also explores the challenges of limited provider networks and the need for patient navigation.